source
- Regenxbio reports positive Duchenne gene therapy trial results, targets FDA approval by 2027Regenxbio announced that its gene therapy for Duchenne muscular dystrophy achieved the required endpoints in a pivotal clinical trial. The data met the study's predefined criteria, which the compa…
- MacroGenics sells manufacturing operations to Bora for $122.5M; West Pharma reports cybersecurity breachMacroGenics announced it is selling its clinical and commercial drug substance manufacturing portfolio to CDMO Bora. The deal includes an upfront payment of $122.5 million. The transaction transfe…